Pipeline-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company

Transcenta is developing a diverse pipeline of more than a dozen novel biologic therapies for oncology and selected non-oncology indications including bone and kidney disorders.

Oncology pipeline includes multiple innovative and differentiated biologic molecules targeting major cancer pathways which have potential synergistic mechanisms of actions for tumor indications with high unmet medical needs. Our pipeline includes both targeted therapy Osemitamab (TST001) as well as immunotherapy (TST005) that engage either NK cells or T cells to kill tumor cells, or agents that can enhance the anti-tumor activity of the above mentioned therapies by either inhibiting tumor associated fibroblast derived immunosuppressive regulatory protein (TST003) or depleting immunosuppressive Treg cells (TST010) or by enhancing TIL infiltration into the tumor by normalizing vasculature (MSB0254).

Transcenta’s highly differentiated non-oncology pipelines focus on novel indications with high unmet medical needs in bone and kidney diseases. TST002 and TST004 are two differentiated molecules that are designed to treat osteoporosis and complement mediated disease respectively. Both osteoporosis and kidney disease like IgAN are areas of high unmet medical needs and with high market potentials.

Oncology

Drugs
Candidate

Target

Indication

Modality

Preclinical

IND

Phase I

Phase II

Pivotal Phase III

Rights

Partner

Osemitamab (TST001)

Claudin 18.2

G/GEJC and Other Solid Tumors

mAb

Osemitamab (TST001)

More + More +

Drugs Candidate:Claudin 18.2

Right:Global

Partner:In-house

Preclinical

IND

Phase I

Phase II

Pivotal Phase III

G/GEJC and Other Solid Tumors -mAb - Combo with PL1/Chemo

Combo with PL1/Chemo

G/GEJC and Other Solid Tumors - - Combo with Chemo

Combo with Chemo

Global

In-house

READ MORE READ MORE

TST106

Claudin 18.2-X

G/ GEJC and other Solid Tumors

BsADC

TST106

More + More +

Drugs Candidate:Claudin 18.2-X

Right:Global

Partner:In-house

Preclinical

IND

Phase I

Phase II

Pivotal Phase III

G/ GEJC and other Solid Tumors -BsADC - Monotherapy

Monotherapy

Global

In-house

READ MORE READ MORE

TST198

Claudin 18.2

G/ GEJC and other Solid Tumors

RDC

TST198

More + More +

Drugs Candidate:Claudin 18.2

Right:Global

Partner:In-house

Preclinical

IND

Phase I

Phase II

Pivotal Phase III

G/ GEJC and other Solid Tumors -RDC - Monotherapy

Monotherapy

Global

In-house

READ MORE READ MORE

TST003

Gremlin-1

Colorectal and Prostate Cancers

mAb

TST003

More + More +

Drugs Candidate:Gremlin-1

Right:Global

Partner:In-house

Preclinical

IND

Phase I

Phase II

Pivotal Phase III

Colorectal and Prostate Cancers -mAb - Monotherapy

Monotherapy

Global

In-house

READ MORE READ MORE

TST786

PD1-VEGF and Gremlin-1

Colorectal and Prostate Cancers

TsAbs

TST786

More + More +

Drugs Candidate:PD1-VEGF and Gremlin-1

Right:Global

Partner:In-house

Preclinical

IND

Phase I

Phase II

Pivotal Phase III

Colorectal and Prostate Cancers -TsAbs - Monotherapy

Monotherapy

Global

In-house

READ MORE READ MORE

TST005

PD-L1 x TGF-β

Solid Tumors

BsAb

TST005

More + More +

Drugs Candidate:PD-L1 x TGF-β

Right:Global

Partner:In-house

Preclinical

IND

Phase I

Phase II

Pivotal Phase III

Solid Tumors -BsAb - Monotherapy

Monotherapy

Global

In-house

READ MORE READ MORE

TST013

LIV-1

Solid Tumors

ADC

TST013

More + More +

Drugs Candidate:LIV-1

Right:Global

Partner:In-house

Preclinical

IND

Phase I

Phase II

Pivotal Phase III

Solid Tumors -ADC - Monotherapy

Monotherapy

Global

In-house

READ MORE READ MORE

TST105

FGFR2b-X

Solid tumors

BsADC

TST105

More + More +

Drugs Candidate:FGFR2b-X

Right:Global

Partner:In-house

Preclinical

IND

Phase I

Phase II

Pivotal Phase III

Solid tumors -BsADC - Monotherapy

Monotherapy

Global

In-house

READ MORE READ MORE

Ozekibart

DR5

Chondrosarcoma

Agonist Antibody

Ozekibart

More + More +

Drugs Candidate:DR5

Right:Greater China

Partner:Inhibrx

Preclinical

IND

Phase I

Phase II

Pivotal Phase III

Chondrosarcoma -Agonist Antibody - Monotherapy

Monotherapy

Greater China

Inhibrx

READ MORE READ MORE

Non-oncology

Drugs
Candidate

Target

Indication

Modality

Preclinical

IND

Phase I

Phase II

Pivotal Phase III

Rights

Partner

Blosozumab (TST002)

Sclerostin

Osteoporosis

mAb

Blosozumab (TST002)

More + More +

Drugs Candidate:Sclerostin

Right:Greater China

Partner:In-licensed from Eli Lilly

Preclinical

IND

Phase I

Phase II

Pivotal Phase III

Osteoporosis -mAb - Monotherapy

Monotherapy

Greater China

In-licensed from Eli Lilly

READ MORE READ MORE

TST004

MASP-2

IgAN, TMA

mAb

TST004

More + More +

Drugs Candidate:MASP-2

Right:Global

Partner:Co-development with Alebund in Greater China

Preclinical

IND

Phase I

Phase II

Pivotal Phase III

IgAN, TMA -mAb - Monotherapy

Monotherapy

Global

Co-development with Alebund in Greater China

READ MORE READ MORE

TST801

BAFF/APRIL

Autoimmune Disease

BsP

TST801

More + More +

Drugs Candidate:BAFF/APRIL

Right:Global

Partner:In-house

Preclinical

IND

Phase I

Phase II

Pivotal Phase III

Autoimmune Disease -BsP - Monotherapy

Monotherapy

Global

In-house

READ MORE READ MORE

TST808

APRIL

IgAN

HLE BpAb

TST808

More + More +

Drugs Candidate:APRIL

Right:Global

Partner:In-house

Preclinical

IND

Phase I

Phase II

Pivotal Phase III

IgAN -HLE BpAb - Monotherapy

Monotherapy

Global

In-house

READ MORE READ MORE

TST008

BAFF/MSAP-2

IgAN

BsAb

TST008

More + More +

Drugs Candidate:BAFF/MSAP-2

Right:Global

Partner:In-house

Preclinical

IND

Phase I

Phase II

Pivotal Phase III

IgAN -BsAb - Monotherapy

Monotherapy

Global

In-house

READ MORE READ MORE